ArticleFrontiers in public health2025
Global, regional, and national prevalence of prostate cancer from 1990 to 2021: a trend and health inequality analyses.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Identifying Distinct Quality-of-Life Profiles in Prostate Cancer Patients: A Latent Profile Approach.Current oncology (Toronto, Ont.) · 2026Article
- The association between diet-exercise patterns and self-reported prostate cancer: A cross-sectional NHANES study.Medicine · 2026Article
- Awareness, risk perception, and attitudes toward prostate cancer detection and MRI among Armenian men.Frontiers in public health · 2026Article
- Differences in adverse drug reactions between GnRH antagonists and agonists in the treatment of prostate cancer: a retrospective analysis using real-world data.Frontiers in pharmacology · 2026Article
- Review
- National Burden of Breast Cancer in Saudi Arabia, 1990-2023, With Forecasts to 2050: A Systematic Analysis for the Global Burden of Disease Study 2023.Evidance health sciences · 2026Article
- Improving Quality of Life Through Supervised Exercise in Oncology: A Systematic Review and Meta-Analysis of Randomized Trials in Breast and Prostate Cancer.Journal of functional morphology and kinesiology · 2025Review
- Patients with Marked Prostatomegaly and Clinically Significant Prostate Cancer Have Inferior Perioperative Outcomes Following Radical Prostatectomy.Journal of clinical medicine · 2025Article
- Global, regional, and national burden of chronic kidney disease and its associated anemia, 1990 to 2021 and predictions to 2050: an analysis of the global burden of disease study 2021.BMC nephrology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prostate cancer in men's health has become a significant driver of global disease burden, impacting aging populations worldwide. This study assesses its prevalence from 1990 to 2021 to reveal ongoing epidemiological trends and inform effective public health strategies. Methods: Prostate cancer prevalence estimates, including their 95% uncertainty intervals (UIs), were derived from the Global Burden of Disease (GBD) 2021 study. Then, temporal trends spanning the past 32 years were thoroughly analyzed using Joinpoint regression, with projections for the next 25 years made using the Bayesian Age-Period-Cohort (BAPC) model. Concurrently, disease trends were decomposed into components of population growth, aging, and epidemiological changes. Additionally, age-period-cohort (APC) models were also employed to explore the impact of age, time, and cohort effect on the relative risk of prostate cancer prevalence. And the cross-country inequalities in the prevalence of prostate cancer burden were meticulously evaluated through the Socio-Demographic Index (SDI), revealing significant disparities across socio-economic strata. Result: In 2021, over 10 million prostate cancer cases were recorded worldwide-a 188.85% increase from 3.6 million in 1990. The age-standardized prevalence rate (ASPR) rose at an estimated annual percentage change of 0.64% (95% UI: 0.47%-0.82%); Joinpoint regression revealed a steady increase in case numbers over 32 years, while the ASPR peaked and then slightly declined. Decomposition analysis showed population growth as the main driver (65.62%), with epidemiological changes and aging accounting for 17.97 and 16.41%, respectively. APC modeling indicated the highest relative risk around age 75-nearly 10 times that of the general population (RR: 9.99; 95% CI: 9.97-10.01). Projections through 2046 forecast a continued rise in both total cases and ASPR. Conclusions: As a major health concern among older adult men, the global prevalence of prostate cancer has risen steadily since 1990, with population growth identified as the primary driver. Moreover, SDI-related disparities across 204 countries and territories have widened over time. Finally, the APC model forecasts a continuous increase in prevalence over the next 25 years, underscoring the growing disease burden and the urgent need for more targeted and effective management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.